CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack - GNPX, BON, SES, BETRF - Stocks to Watch Now!

CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fast Track - GNPX, BON, SES, BETR.C - Stocks to Watch

CS Diagnostics Corp. (OTCQB: CSDX) has engaged Lachman Consultants Inc. to support FDA approval for its CS-Protect Hydrogel, an innovative organ spacer medical device designed to enhance radiation therapy outcomes. Approval is expected within 3-4 months, with U.S. production targeted for early 2026.

CS-Protect Hydrogel offers a breakthrough in cancer radiology, eliminating contamination risks and ensuring precise treatment application. Lachman Consultants, a leader in regulatory compliance since 1978, will assist in streamlining the approval process.

Vice President Mohammad EsSayed noted that Boston Scientific previously acquired a similar product for $500 million, underscoring the strong market potential. As an OTCQB-listed company, CS Diagnostics Corp. offers a high-growth investment opportunity in medical device innovation.

Other Developing Growth Stocks to Watch in 2025

Genprex, Inc. (NASDAQ: GNPX) is advancing its diabetes gene therapy program through a strategic collaboration with a CDMO to develop a next-generation non-viral lipid nanoparticle delivery system. A leader in gene therapy for cancer and diabetes, Genprex utilizes its Oncoprex Registered Delivery System for targeted tumor suppression and its GPX-002 therapy to restore insulin production. The company's lead candidate, Reqorsa Registered Gene Therapy, is in clinical trials for lung cancer, with FDA Fast Track and Orphan Drug Designations, reinforcing its mission to deliver breakthrough treatments for underserved patients.

Bon Natural Life (Nasdaq: BON) Raises $12M in Best Efforts Offeringof 8.33 million Class A ordinary shares (or pre-funded warrants), along with Series A and B Warrants at $1.44 and $2.16 per share, respectively. The Warrants are immediately exercisable, with a three-year expiration. Proceeds will fund sales expansion, R&D, production growth, and working capital. The offering is set to close around March 18, 2025, pending customary conditions.

SES AI Corp (NYSE: SES) Advances Lithium-Metal Battery Technology for EVs and eVTOL and is pioneering high-performance Lithium-Metal (Li-Metal) rechargeable battery technologies for electric vehicles (EVs), eVTOL aircraft, and other applications. As an integrated Li-Metal battery manufacturer, SES develops materials, cells, modules, AI-powered safety algorithms, and recycling solutions, positioning itself at the forefront of next-generation energy storage innovation.

BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) Secures Key Patent for BETR-001. BetterLife Pharma Inc. has been granted a composition of matter patent (US2023/0219955) for BETR-001, a non-hallucinogenic LSD derivative in development for major depressive disorder, anxiety, and neuropathic pain, extending protection until 2042. With multiple patents covering its synthesis and use, BETR-001 eliminates regulatory hurdles as an uncontrolled substance. The company is also developing BETR-002, a honokiol-based therapy for anxiety disorders, while seeking strategic alternatives for its antiviral drug candidate.

As CS Diagnostics Corp. (OTCQB: CSDX) fast-tracks its FDA approval, Genprex (NASDAQ: GNPX) advances gene therapy, Bon Natural Life (Nasdaq: BON) secures funding, SES AI (NYSE: SES) accelerates battery innovation, and BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) strengthens its IP portfolio, these companies are making significant strides in their respective industries, presenting potential investment opportunities for market watchers.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cs-diagnostics-otcqb-csdx-csprotect-hydrogel-fda-approval-on-fasttrack-gnpx-bon-ses-betrf-stocks-to-watch-now]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.